Evidence map›Paper›PMID 21248041›Full record

ArticleJournal of virology2011

Vital role for CD8+ cells in controlling retroviral infections.

Melissa Kane, Laure K Case, Tatyana V Golovkina

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.1field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. MHC Class II Presentation Is Affected by Polymorphism in theJournal of immunology (Baltimore, Md. : 1950) · 2021
    Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Melissa KaneDepartment of Microbiology, University of Chicago, 920 E. 58th Street, Chicago, IL 60637, USA.
Laure K Case
Tatyana V Golovkina
University of Chicago · US

Funding

VIRAL ONCOLOGY CORE FACILITYP30CA014599 · NCI · UNIVERSITY OF CHICAGO · PI MARK W. LINGEN · 1985 to 2026
$122.1M
Cloning of the vic1 gene, a novel retrovirus restriction factorR01CA134667 · NCI · UNIVERSITY OF CHICAGO · PI GOLOVKINA, TATYANA V · 2008 to 2012
$1.7M
Mechanism of Resistance to MMTV Induced Mammary TumorsR01CA089116 · NCI · UNIVERSITY OF CHICAGO · PI GOLOVKINA, TATYANA V · 2001 to 2008
$1.4M
NCI NIH HHS CA1134667NCI NIH HHS CA89116NCI NIH HHS P30 CA014599NCI NIH HHS R01 CA089116NCI NIH HHS R01 CA134667
6 · The paper itself

Abstract

Antiviral adaptive immune defenses consist of humoral and cell-mediated responses, which together eliminate extracellular and intracellular virus. As most retrovirus-infected individuals do not raise efficient protective antivirus immune responses, the relative importance of humoral and cell-mediated responses in restraining retroviral infection is not well understood. We utilized retrovirus-resistant I/LnJ mice, which control infection with mouse mammary tumor virus (MMTV) and murine leukemia virus (MuLV) via an adaptive immune mechanism, to assess the contribution of cellular responses and virus-neutralizing antibodies (Abs) to the control of retroviral infection. We found that in retrovirus-infected CD8-deficient I/LnJ mice, viral titers exceed the neutralizing capability of antiviral Abs, resulting in augmented virus spread and disease induction. Thus, even in the presence of robust neutralizing Ab responses, CD8-mediated responses are essential for full protection against retroviral infection.

Indexed as

AnimalsAntibodies, NeutralizingAntibodies, ViralCD8-Positive T-LymphocytesLeukemia Virus, MurineMammary Tumor Virus, MouseMiceRetroviridae InfectionsAntibodies, NeutralizingAntibodies, Viral

Identifiers

PMID21248041
PMCPMC3067886
OpenAlexW2115801647

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.